Oncology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

HER2+ breast carcinoma: Lapatinib and Trastuzumab shrinks cancer in 11 days after diagnosis

Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs Lapatinib /( Tyverb; Tykerb ) and Trastuzumab ( Herceptin ) before surgery and chemotherapy, saw their tumours shrink significantly or even disappear.

The results from UK EPHOS-B multi-centre, clinical trial, in which 257 women with newly-diagnosed, operable, HER2 positive disease were recruited during 2010-2015 period, were presented at 10th European Breast Cancer Conference ( EBCC-10 ).

The trial had two parts; in part one, 130 women were randomised to receive no pre-operative treatment ( control group ), or Trastuzumab only, or Lapatinib only, for 11 days after diagnosis and before surgery.
However, as evidence emerged from other trials of the efficacy of the combination of Lapatinib and Trastuzumab to treat HER2 positive breast cancer in other settings, the second part of the trial was amended so that, from August 2013, the next 127 women were randomised to the control group, or to receive Trastuzumab only, or the combination treatment.
For both parts of the trial, the women continued to receive standard of care treatment after surgery.

Samples of tumour tissue were taken from the first biopsy, which had been used to confirm the cancer diagnosis, and then again during surgery. The samples were analysed to see if there had been a drop in levels of the Ki67 protein, an indicator of cell proliferation, or a rise in apoptosis ( programmed cell death ) of 30% or more from the time of the first biopsy.

In addition, researchers reviewed the pathology reports on the tissue taken during surgery, and the women were then categorised as either having pathological complete response ( pCR ) if no active cancer cells had been found, minimal residual disease ( MRD ) if the tumour was less than 5mm in diameter, or other.

Results from the second part of the trial, analysed in February 2016, showed that, in addition to observing a drop in Ki67, for women who received the combination treatment 11% had pCR and 17% had MRD.
For those women randomised to receive only Trastuzumab, 0% had pCR and 3% had MRD and no patients had either pCR or MRD in the control group.

The group of women who responded to the combination treatment included women who had presented with stage 2 breast cancer ( where it had spread to their lymph nodes ).

These results have shown that it’s possibile an early indication of pathological response within 11 days, in the absence of chemotherapy, in these patients on combination treatment.
Most previous trials have only looked at the pathological response after several months of treatment.
Clearly these results need further confirmation.

EPHOS-B is the only trial that has investigated giving combination treatment alone, without chemotherapy, in the two weeks between diagnosis and routine surgery. Other trials have looked at anti-HER2 therapy, with and without chemotherapy, including an assessment of the combination of Trastuzumab and Lapatinib, and have reported impressive response rates but these trials have only reported results after several months of therapy.
Potentially, giving treatment while waiting for surgery can identify a group of patients whose disease is particularly sensitive to anti-HER2 therapy, which would allow individualisation of therapy in women with HER2 positive cancers.

HER2 positive breast cancer is breast cancer that has a high number of receptors for the human epidermal growth factor ( HER2 ) on the surfaces of the cancer cells.
These receptors stimulate the cancer cells to divide and grow. HER2 positive breast cancers tend to grow more quickly than HER2 negative cancers but can be treated with targeted therapies such as Trastuzumab and Lapatinib. ( Xagena )

Source: ECCO – The European Cancer Organization, 2016